<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359186</url>
  </required_header>
  <id_info>
    <org_study_id>20-30442</org_study_id>
    <nct_id>NCT04359186</nct_id>
  </id_info>
  <brief_title>SCOPE Analytic Treatment Interruption Protocol</brief_title>
  <acronym>SCOPE-ATI</acronym>
  <official_title>Analytic Treatment Interruption in HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chan Zuckerberg Biohub</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to understand the interaction between HIV and the host at the&#xD;
      earliest stages when HIV medications are paused. Volunteers with HIV will interrupt&#xD;
      antiretroviral therapy (ART) and then have intensive studies preformed two to three times per&#xD;
      week. Most will resume therapy within three weeks, even if the virus does not rebound during&#xD;
      this time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, people living with HIV will undergo intensive sampling prior to and following&#xD;
      an interruption of their antiretroviral therapy (ART). Individuals will be asked to resume&#xD;
      ART once the virus is detectable, or after approximately three weeks if the virus remains&#xD;
      undetectable.&#xD;
&#xD;
      Individuals who were able to control their virus before ART (&quot;controllers&quot;) will be able to&#xD;
      participate in an extended treatment interruption and have less restrictive ART restart&#xD;
      criteria.&#xD;
&#xD;
      The overall goal of the study is to characterize the interaction between the host and the&#xD;
      virus at the earliest stages of virus replication and to identify predictors of rebound&#xD;
      before virus becomes detectable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute retroviral syndrome</measure>
    <time_frame>Week 0 through Month 6</time_frame>
    <description>The proportion of participants developing acute retroviral syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure to re-suppress</measure>
    <time_frame>Week 0 through Month 12</time_frame>
    <description>The proportion of participants who fail to re-suppress to plasma HIV RNA levels &lt;50 copies/mL after re-initiating ART</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4+ T cell decline</measure>
    <time_frame>Week 0 through Month 6</time_frame>
    <description>The proportion of participants with confirmed decreases in CD4+ T cell count below 350 cells/uL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to rebound</measure>
    <time_frame>Week 0 through Month 6</time_frame>
    <description>The time between the treatment interruption and plasma HIV RNA &gt;200 copies/mL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Treatment Interruption Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment Interruption Arm</intervention_name>
    <description>Individuals with HIV on suppressive ART will interrupt their ART.</description>
    <arm_group_label>Treatment Interruption Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Age &gt;= 18&#xD;
&#xD;
          -  Documented HIV infection&#xD;
&#xD;
          -  Antiretroviral therapy for at least 12 months&#xD;
&#xD;
          -  Screening plasma HIV RNA levels below level of detection (&lt; 40-75 copies/mL), and all&#xD;
             available determinations in past 12 months also below level of detection (blips&#xD;
             allowed)&#xD;
&#xD;
          -  Screening CD4+ T-cell count &gt;350 cells/uL&#xD;
&#xD;
          -  If of childbearing potential, willing to use two methods of contraception&#xD;
&#xD;
          -  Willing to receive counseling regarding HIV transmission risk mitigation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or plans to become pregnant during the course of the study&#xD;
&#xD;
          -  Active hepatitis B, defined as (1) positive sAg or (2) positive cAb with negative sAb&#xD;
             and positive HBV DNA&#xD;
&#xD;
          -  Active hepatitis C, defined as positive Hep C Ab with positive HCV RNA&#xD;
&#xD;
          -  Use of a non-nucleoside reverse transcriptase inhibitor and unable to switch regimen&#xD;
&#xD;
          -  Significant cardiovascular or cerebrovascular disease&#xD;
&#xD;
          -  Recent or prior (within past 5 years) malignancy&#xD;
&#xD;
          -  Severe kidney disease (CrCl &lt; 50 mL/min via Cockroft-Gault method)&#xD;
&#xD;
          -  Severe hepatic impairment (Child-Pugh Class C) or unstable liver disease&#xD;
&#xD;
          -  Concurrent treatment with immunomodulatory drugs&#xD;
&#xD;
          -  Unable or unwilling to use barrier protection or pre-exposure prophylaxis (PrEP) to&#xD;
             prevent HIV transmission with sexual partners not known to be HIV-infected&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Deeks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>HIV/AIDS</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>HIV reservoir</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

